Jefferies Group's SRPT Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 78,980 shares of Sarepta Therapeutics, Inc. (SRPT) worth $1.72 M, representing 0.01% of the portfolio. First purchased in 2022-Q4, this medium-term investment has been held for 10 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in SRPT, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 78,980 shares. Largest reduction occurred in Q1 2023, reducing 62,335 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Sarepta Therapeutics (SRPT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Sarepta Therapeutics (SRPT) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +78,980 | New Buy | 78,980 | $21.76 |
| Q3 2025 | -1,068 | Sold Out | 0 | $0.00 |
| Q2 2025 | +1,068 | New Buy | 1,068 | $17.10 |
| Q2 2024 | -7,800 | Sold Out | 0 | $0.00 |
| Q1 2024 | -57,933 | Reduce 88.13% | 7,800 | $129.46 |
| Q4 2023 | +65,733 | New Buy | 65,733 | $96.43 |
| Q3 2023 | -3,494 | Sold Out | 0 | $0.00 |
| Q2 2023 | -3,463 | Reduce 49.78% | 3,494 | $114.52 |
| Q1 2023 | -62,335 | Reduce 89.96% | 6,957 | $137.83 |
| Q4 2022 | +69,292 | New Buy | 69,292 | $129.58 |
Jefferies Group's Sarepta Therapeutics Investment FAQs
Jefferies Group first purchased Sarepta Therapeutics, Inc. (SRPT) in Q4 2022, acquiring 69,292 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Sarepta Therapeutics, Inc. (SRPT) for 10 quarters since Q4 2022.
Jefferies Group's largest addition to Sarepta Therapeutics, Inc. (SRPT) was in Q1 2026, adding 78,980 shares worth $1.72 M.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 78,980 shares of Sarepta Therapeutics, Inc. (SRPT), valued at approximately $1.72 M.
As of the Q1 2026 filing, Sarepta Therapeutics, Inc. (SRPT) represents approximately 0.01% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Sarepta Therapeutics, Inc. (SRPT) was 78,980 shares, as reported at the end of Q1 2026.